| Identification | Back Directory | [Name]
α-D-Glucopyranose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-2-[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-, 3-[(3R)-3-hydroxytetradecanoate], ammonium salt (1:1) | [CAS]
1332714-01-8 | [Synonyms]
PHAD-504
α-D-Glucopyranose, 2-deoxy-6-O-[2-deoxy-2-[[(3R)-1-oxo-3-[(1-oxododecyl)oxy]tetradecyl]amino]-3-O-[(3R)-1-oxo-3-[(1-oxotetradecyl)oxy]tetradecyl]-4-O-phosphono-β-D-glucopyranosyl]-2-[[(3R)-3-hydroxy-1-oxotetradecyl]amino]-, 3-[(3R)-3-hydroxytetradecanoate], ammonium salt (1:1) | [Molecular Formula]
C94H180N3O22P | [MOL File]
1332714-01-8.mol | [Molecular Weight]
1735.45 |
| Hazard Information | Back Directory | [Description]
PHAD?-504 was designed as a synthetic structural analog of detoxified MPLA derived from E. coli lipopolysaccharide (LPS). It is structurally similar to PHAD?, differing only in the length of a single fatty acid chain. As expected, the activity of PHAD?-504 is quite similar to that of PHAD?, making the two products interchangeable as adjuvants in vaccine or immunotherapy formulations. |
|
|